Bevacizumab in combination with taxanes for the first-line treatment of metastatic breast cancer.
Explore this paper's citation graph
Summary
Bevacizumab-taxane combinations provide an alternative to chemotherapy doublet regimens in first-line mBC, with equivalent efficacy and potentially lower toxicity, and the tolerability of bevacizUMab- Taxane combinations compares favourably with that of taxanes in combination with other chemotherapy agents.
- Type
- article
- Published
- 2010-12-01
- Cited by
- 45
- References
- 77
- Access
- Open access
- OpenAlex
- https://openalex.org/W20335367
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:8301385
Keywords
Geology
References
- Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer
- RiBBON 1 and RiBBON 2: phase III trials of bevacizumab with standard chemotherapy for metastatic breast cancer.
- Single agent versus combination chemotherapy for metastatic breast cancer.
- Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.
- Cancer : Principles and Practice of Oncology
- Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: final results of a randomized phase III multicenter trial.
- Accelerated Metastasis after Short-Term Treatment with a Potent Inhibitor of Tumor Angiogenesis
- Future use of bevacizumab and other anti-angiogenic agents in breast cancer
- Tumor angiogenesis: therapeutic implications.
- Recombinant factor VIIa in the management of pulmonary hemorrhage associated with metastatic choriocarcinoma.
- A systematic review of taxane-containing regimens for metastatic breast cancer
- RIBBON-2: A Randomized, Double-Blind, Placebo-Controlled, Phase III Trial Evaluating the Efficacy and Safety of Bevacizumab In Combination with Chemotherapy for Second-Line Treatment of HER2-Negative Metastatic Breast Cancer.
- A small molecule–kinase interaction map for clinical kinase inhibitors
- 5017 Multinational study (n = 2041) of first-line bevacizumab (Bev) plus taxane-based chemotherapy (CT) for locally recurrent or metastatic breast cancer (LR/mBC): updated results of MO19391
- Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193).
- A phase-III trial of doxorubicin and docetaxel versus doxorubicin and paclitaxel in metastatic breast cancer: results of the ERASME 3 study
- Managing Patients Treated with Bevacizumab Combination Therapy
- Triple negative breast cancer: a phase 2, multi-center, open-label, randomized trial of gemcitabine/carboplatin (G/C), with or without BSI-201, a PARP inhibitor.
- No Clinical Evidence for Increase in Tumour Malignant Potential in Patients (Pts) with Metastatic Breast Cancer (mBC) Treated with Bevacizumab (BV) and Docetaxel (D) in the Phase III AVADO Study.
- Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts.
Cited by
- Bevacizumab and breast cancer: the E2100 outlier.
- Critical issues on high-dose chemotherapy with autologous hematopoietic progenitor cell transplantation in breast cancer patients
- Safety and Efficacy of Docetaxel, Bevacizumab, and Everolimus for Castration-resistant Prostate Cancer (CRPC)
- Development of targeted anticancer agents using novel N-alkylisatin derivatives
- Cancer du sein métastatique
- Influence of Alternative Tubulin Inhibitors on the Potency of a Epirubicin-Immunochemotherapeutic Synthesized with an Ultra Violet Light-Activated Intermediate
- Efficacy and safety of bevacizumab in combination with docetaxel for the first-line treatment of elderly patients with locally recurrent or metastatic breast cancer: results from AVADO.
- The Impact of Bevacizumab (Avastin) on Survival in Metastatic Solid Tumors - A Meta-Analysis and Systematic Review
- Neoadjuvant bevacizumab: surgical complications of mastectomy with and without reconstruction
- Benefit-Risk Assessment of Bevacizumab in the Treatment of Breast Cancer
- Through a glass darkly: advances in understanding breast cancer biology, 2000-2010.
- Nab-paclitaxel/bevacizumab/carboplatin chemotherapy in first-line triple negative metastatic breast cancer.
- Mechanisms of Resistance to Trastuzumab and Novel Therapeutic Strategies in HER2-Positive Breast Cancer
- Enhancing intracellular taxane delivery: current role and perspectives of nanoparticle albumin-bound paclitaxel in the treatment of advanced breast cancer
- Cáncer de mama metastásico
- Maintenance bevacizumab beyond first-line paclitaxel plus bevacizumab in patients with Her2-negative hormone receptor-positive metastatic breast cancer: efficacy in combination with hormonal therapy
- Vascular endothelial growth factor ‑634G/C polymorphism is associated with increased breast cancer risk and aggressiveness.
- Investigation of antitumor effects of sorafenib and lapatinib alone and in combination on MCF-7 breast cancer cells.
- Taxanes: promising anti-cancer drugs.
- Treatment options for patients with triple-negative breast cancer
Related papers
No related papers recorded.